Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Howard Williams who wrote (11509)	9/21/2012 7:19:02 AM
From: NTTG	Read Replies (1) \| Respond to of 13111

Smart move by Pfizer to protect their sunitinib interest. FDA clearly signaling to PVCT that the next step liver trial will need to be a combination therapy protocol with Pfizer's drug (they dont trust PV-10 alone?), PVCT has probably approach Pfizer for free drug for the planned trial, low risk for Pfizer at this point.

To: Howard Williams who wrote (11509)	9/26/2012 7:18:40 PM
From: Cal Amari	4 Recommendations Read Replies (1) \| Respond to of 13111

The document linked to your email (International Patent Application Publication No. WO/2012/122444) is a published PCT application. An application under the Patent Cooperation Treaty is centrally examined and results in issuance of a non-binding examination report ("International Preliminary Report on Patentability" or IPRP). Patent rights are ultimately granted on a national basis. If the applicant (or in this case, the joint applicants Provectus and Pfizer ...) chooses to seek national patent protection, then the deadline for filing regional/national applications is nominally 30 months from the earliest priority date of 3/10/2011 - so the nominal regional/national phase deadline will be 9/10/2013. The PCT proceedings can be monitored using the following link: patentscope.wipo.int The next major event in this application will be issuance of the International Search Report and Written Opinion. If the ISR/WO is positive, then the IPRP will reiterate the findings of the WO. Certain jurisdictions (e.g., Singapore and Malaysia) will confer automatic patent allowance if a patent applicant presents a positvie IPRP and pays a national fee. In most jurisdictions, however, a supplemental search and examination are performed, such that a positive result in the international phase of the PCT does not always translate into a national patent. It will be interesting to see the progress of this application. As a longtime PVCT shareholder, I am heartened at the news that PFE and PVCT are collaborating on IP.